185 related articles for article (PubMed ID: 34013205)
1. H3K27M and
Osada Y; Saito R; Shibahara I; Sasaki K; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Watanabe M; Tominaga T
Neurooncol Adv; 2021; 3(1):vdab038. PubMed ID: 34013205
[TBL] [Abstract][Full Text] [Related]
2. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of HIST1H3B/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
Vuong HG; Ngo TNM; Le HT; Dunn IF
J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
5. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients.
Qu CX; Ji HM; Shi XC; Bi H; Zhai LQ; Han DW
Brain Behav; 2020 Apr; 10(4):e01583. PubMed ID: 32146731
[TBL] [Abstract][Full Text] [Related]
7. Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines.
Bai H; Bai S; Li X; Zhang Y; Li Y; He F; Cheng W
Biomed Res Int; 2021; 2021():3271395. PubMed ID: 34159191
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas.
Vuong HG; Ngo TNM; Le HT; Jea A; Hrachova M; Battiste J; McNall-Knapp R; Dunn IF
Front Oncol; 2022; 12():858148. PubMed ID: 35371982
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Molecular Characteristics of Thalamic Gliomas: Retrospective Report of 26 Cases.
Liu Y; Zhang Y; Hua W; Li Z; Wu B; Liu W
World Neurosurg; 2019 Jun; 126():e1169-e1182. PubMed ID: 30885860
[TBL] [Abstract][Full Text] [Related]
10. Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.
Cao W; Lan J; Hu C; Kong J; Xiang L; Zhang Z; Sun Y; Zeng Z; Lei S
Aging (Albany NY); 2024 Mar; 16(6):5618-5633. PubMed ID: 38499392
[TBL] [Abstract][Full Text] [Related]
11. Adult IDH wild-type lower-grade gliomas should be further stratified.
Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
[TBL] [Abstract][Full Text] [Related]
12. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
Front Oncol; 2020; 10():795. PubMed ID: 32582540
[No Abstract] [Full Text] [Related]
13. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
[TBL] [Abstract][Full Text] [Related]
14.
Picca A; Berzero G; Bielle F; Touat M; Savatovsky J; Polivka M; Trisolini E; Meunier S; Schmitt Y; Idbaih A; Hoang-Xuan K; Delattre JY; Mokhtari K; Di Stefano AL; Sanson M
Neurology; 2018 Jun; 90(23):e2086-e2094. PubMed ID: 29728520
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
16. Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.
Grimaldi S; Harlay V; Appay R; Bequet C; Petrirena G; Campello C; Barrié M; Autran D; Boissonneau S; Graillon T; Figarella-Branger D; Nanni I; Chinot O; Tabouret E
J Neurooncol; 2022 Feb; 156(3):615-623. PubMed ID: 34994963
[TBL] [Abstract][Full Text] [Related]
17. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
19. The Role of Surgery in IDH-Wild-Type Lower-Grade Gliomas: Threshold at a High Extent of Resection Should be Pursued.
Wang P; Luo C; Hong PJ; Rui WT; Wu S
Neurosurgery; 2021 May; 88(6):1136-1144. PubMed ID: 33647953
[TBL] [Abstract][Full Text] [Related]
20. H3K27M mutant glioma: Disease definition and biological underpinnings.
Saratsis AM; Knowles T; Petrovic A; Nazarian J
Neuro Oncol; 2024 May; 26(Supplement_2):S92-S100. PubMed ID: 37818718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
